EGFR and ovarian cancer: The concurrent activation of multiple signaling pathways, including EGFR, PI3/AKT, MEK/ERK and JAK/STAT3, appears to be more common in ovarian cancer and raises an important question about the involvement of these signaling pathways in the development of drug resistance [4].